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Indications and the type of antithrombotic therapy for
the prevention of thromboembolism in patients with val-
vular heart disease, mechanical prosthetic heart valves
and bioprosthetic heart valves are discussed. The evi-
dence for these clinical recommendations is described
and graded into five levels. The indications for antico-
agulation in patients with valvular heart disease are
chronic or paroxysmal atrial fibrillation, sinus rhythm
with a very large left atrium, severe left ventricular dys-
function or presence of heart failure or a history of pre-
vious thromboembolism. Anticoagulant therapy is ad-
ministered to prolong the prothrombin time to 1.5 to 2.0
times control, using rabbit brain thromboplastin (stan-
dardized international normalized ratio = 3.0 to 4.5).
Risk factors for thromboembolism in patients with
prosthetic heart valves are discussed. Because intracar-
diac thrombus formation may start during and continues
Valvular Heart Disease
Incidence of Thromboembolism
The incidence of arterial thromboembolism in patients
with valvular heart disease varies depending on the partic-
ular valve involved, the degree of left ventricular dysfunc-
tion, the degree of left atrial enlargement and the presence
or absence of atrial fibrillation (1-6). Thromboembolism is
a clinical diagnosis. It commonly involves the brain. in
which case a useful definition is a temporary or permanent
neurologic deficit of sudden onset with focal motor weak-
ness or visual deficit. Emboli may also involve the coronary
circulation, the limbs, the kidneys, the splanchnic bed or
the spleen. The effects of thromboemboli can be categorized
as follows: 1) minor or transient, 2) major with permanent
residua or need for operation. 3) or fatal. Unfortunately.
this has not often been recorded in published studies. As
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early after operation, restarting heparin therapy 6 hours
after operation and continuing it for the duration of the
hospitalization is advised. For mechanical prosthetic
heart valves, oral anticoagulation as outlined plus di-
pyridamole is advised indefinitely. Platelet inhibitor
therapy alone is insufficient. For bioprosthetic heart
valves, heparin is followed by oral anticoagulation as
outlined for 3 months after mitral or aortic valve re-
placement and indefinitely after mitral valve replace-
ment if there is atrial fibrillation or a very large left
atrium; aspirin may be recommended indefinitely after
aortic valve replacement. Antithrombotic therapy is also
considered for four special situations: 1) noncardiac sur-
gery, 2) prosthetic valve endocarditis, 3) anticoagulation
after a thromboembolic event, and 4) antithrombotic
therapy during pregnancy.
(J Am Coli CardioI1986;8:41B-56B)
discussed more fuBy under the section on prosthetic heart
valves, the incidence of thromboembolism may be difficult
to ascertain and compare from study to study because of
poor definition of an event and inadequate reporting of lin-
earized or actuarial rates.
Mitral stenosis. Mitral stenosis with or without regur-
gitation is the most common form of valvular disease as-
sociated with thromboembolism. Thrombi are localized with
about equal frequency either in the left atrial appendage or
on the left atrial wall. Thromboembolism may be the pre-
senting symptom in more than 10% of patients with mitral
stenosis. It can occur with all degrees of stenosis, and has
an estimated incidence of between 1 and 5% per year, with
up to 16% of the events being fatal (1,4,6-12). The presence
of atrial fibrillation increases the risk of thromboembolism
by three to seven times (4,6) or even up to an 18-fold
increase as estimated by the Framingham Study (3).
Mitral incompetence. Thromboembolism is much less
common in patients with mitral incompetence; the estimated
incidence is between 1 and 3% per year (4,6,11). There
appears to be a higher incidence in patients with severe
mitral incompetence. especially if there is coexistent mitral
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stenosis, with estimates being up to 4% per year (4) or
involving 14 to 18% of patients (4,6). In 65 patients with
severe mitral incompetence followed up for at least 10 years
at the Mayo Clinic (13), the incidence of thromboembolic
events was 2.9% per year. Thus, mitral incompetence ap-
pears to be associated with a significant risk of thromboem-
bolism.
Mitral valve prolapse. Mitral valve prolapse is ex-
tremely common. It occurs in 2 to 6% of the general pop-
ulation when diagnosed by auscultatory and echocardio-
graphic criteria (14-16), and may occur in up to 17% of
young women and girls (15). A causal relation between
cerebral ischemic events and mitral valve prolapse was first
proposed over a decade ago (17). However, it is difficult
in the individual patient to establish convincingly a causal
relation between the valvular disease and the cerebral isch-
emia. Other more common causes of cerebral ischemia must
be excluded before implicating mitral valve prolapse (18).
In a recent long-term follow-up of 237 patients with
mitral valve prolapse documented by echocardiography (14),
complications were most frequent in patients with redundant
mitral valve leaflets. Of the 10 patients with a cerebral
embolic event, 2 had other predisposing factors (left ven-
tricular aneurysm with thrombus in 1 and infective endo-
carditis in the other). Of the remaining eight patients, six
had atrial fibrillation with an enlarged left atrium. Thus,
only two patients did not have atrial fibrillation and had no
other predisposing causes (one with and one without re-
dundant mitral leaflets).
Embolism of valvular thrombi is the most likely mech-
anism of cerebral events associated with mitral v;lve pro-
lapse (16,17,19). Another possible nonseptic cause is em-
bolism of left atrial thrombi associated with atrial fibrillation.
Fortunately, most cerebral events associated with mitral valve
prolapse are transient ischemic attacks or small strokes.
Massive infarction is uncommon in the absence of atrial
fibrillation (20,21).
Aortic valve disease. Thromboembolism due to aortic
valve disease is much less frequent than that due to mitral
valve disease and is usually associated with endocarditis,
atrial fibrillation or coexistent mitral valve disease (22-24).
The precise incidence is not well documented. In a Mayo
Clinic series (13) of 68 medically treated patients with sig-
nificant aortic incompetence, the incidence of embolism was
0.83% per year and it occurred in 4.4% of patients followed
up for at least 10 years.
Most emboli in aortic stenosis are calcareous and may
be clinically silent (25,26). An embolus may be the first
indication of calcific aortic stenosis. An increased severity
of valvular stenosis does not increase the risk of embolism.
Unless great care is taken, emboli may be dislodged during
cardiac catheterization or at surgery and can be a significant
problem. Pathologic specimens have demonstrated platelet
fibrin thrombi on disrupted valvular endothelium (27). Clin-
ically, retinal artery occlusive events or transient monocular
blindness occurs more frequently than brain infarction, sug-
gesting that the emboli associated with calcific aortic ste-
nosis are usually relatively small (18).
Risk Factors for Systemic Embolism
Atrial fibrillation. Atrial fibrillation is the most impor-
tant factor predisposing to thromboembolism in patients with
valvular heart disease; embolism is much less frequent in
patients wtih normal sinus rhythm (3-6,11,28,29). The in-
cidence of atrial fibrillation increases sharply with age in
both sexes (30). In valvular heart disease, atrial fibrillation
is nearly always associated with mitral valve disease, and
embolic episodes frequently occur early after the onset of
atrial fibrillation. In one study (6), 33% of emboli occurred
within 1 month and 66% occurred within 12 months of the
onset of atrial fibrillation. Thus, it is important to anticipate
the risk of atrial fibrillation in patients who have a very
large left atrium.
Left atrial size. Considerable enlargement of the left
atrium is found mainly in patients with mitral valve disease.
However, in patients with preexisting atrial fibrillation and
mitral valve disease, the degree of left atrial enlargement
assessed by M-mode echocardiography is not an indepen-
dent risk factor for the development of thromboembolism
(2.8). Atrial fibrillation is much more common in patients
WIth a very large left atrium. Thus, left atrial enlargement
in patients with sinus rhythm may indirectly lead to throm-
boembolism by predisposing to atrial fibrillation. This is the
r~tional~ for instituting prophylactic anticoagulation in pa-
tIents WIth a very large left atrium.
Previous embolism. After an initial embolus in patients
with valvular heart disease, recurrent embolism occurs in
30 to 75% of patients or at a rate of nearly 10% per year
(5-7,31-33). Recurrent embolism is especially common
during the first year, with most events occurring within 6
months of the initial event (6,7). The mortality rate from
recurrent emboli, which can occur in up to 20% of patients
with mitral stenosis, may be as high as 42% (6,10).
Other factors. The correlation between the likelihood
of embolism and the severity of the patient's symptoms is
not strong (4,11), and symptomatic relief after successful
mitral valvotomy does not eliminate the risk of recurrent
embolism (4,9). Low cardiac output was identified as an
important risk factor (4,6) for embolism in one study (28).
Age also appeared to be an independent risk factor, but this
may be related in part to a higher incidence of atrial fibril-
lation (30). The first embolus most commonly occurs during
the fourth decade of life, and up to 38% of patients will
have had embolism by the seventh decade (34).
Recommendations for Antithrombotic Therapy
Clinical indications. The general indications for anti-
coagulation in patients who have valvular heart disease are
outlined in Table 1. Evidence for clinical recommendations
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Table 1. Valvular Heart Disease: Indications
for Anticoagulation*
I. Atnal fibrillation (chrome or paroxysmal)
2 SInUS rhythm with a very large left atrium (> 55 mm by M-mode
echocardiography)
3. Presence of heart failure or severe left ventncular dysfunction
4. History of previous systemic embohsm
*ProthrombIn time to 1.5 to 2.0 times control, using rabbit brain throm-
boplastin (standardized international normalized ratio = 3.0 to 4.5).
on the use of antithrombotic agents can be classified into
five levels, as previously described (35).
Level I studies are randomized trials with low false pos-
itive (a) errors (for example, the aortocoronary bypass trial
by Chesebro et al. [36], in which a convincing and statis-
tically significant benefit from experimental treatment with
anitiplatelet therapy in decreasing occlusion of vein grafts
was found, with a p = 10- 6 or 95% confidence interval
for the difference well away from zero [16 to 35%]) and
low false negative (f3) errors (high power, for example, the
lack of benefit of sulfinpyrazone in a large trial [37] of
patients with unstable angina, in which the 95% confidence
interval excluded any practical possibility that sulfinpyra-
zone could halve the risk of cardiac death and myocardial
infarction) .
Level II studies are randomized trials with high false
positive (a) errors, high false negative ({3) errors (low power,
such as five of the six trials with aspirin therapy after myo-
cardial infarction that showed positive but statistically in-
significant trends favoring aspirin) or both errors.
Level III studies are nonrandomized, concurrent, cohort
comparisons between patients who did and did not receive
antithrombotic therapy.
Level IV studies are nonrandomized, historical, cohort
comparisons between current patients who received anti-
thrombotic therapy and former patients who did not ('his-
torical controls').
Level V studies are case series without controls.
From these five levels of study are derived grade A rec-
ommendations that are supported by at least one, and pref-
erably more, level I randomized trial or trials. Grade B
recommendations are supported by at least one level II ran-
domized trial. Grade C recommendations are supported only
by level III, IV or V studies.
Therapeutic prothrombin time range. The therapeutic
range for oral anticoagulant therapy may differ depending
on the thromboembolic risk. The therapeutic range is now
lower than previously realized for patients with venous
thrombosis (prothrombin time prolonged to 1.2 to 1.5 times
control, using rabbit brain thromboplastin [as used in more
than 90% of laboratories in the United States]; standardized
international normalized ratio [INR] = 2.0 to 3.0, grade A
recommendation [38], but it is less well established in val-
vular heart disease [grade C recommendations]). Currently,
we recommend long-term warfarin therapy to prolong the
prothrombin time to 1.5 to 2.0 times control, using rabbit
brain thromboplastin (standardized INR = 3.0 to 4.5) for
all of the indications listed in Table I. However, hypotheses
that need testing in future trials are that higher risk patients,
those with a documented systemic embolism (indication 4
in Table I) or those with two or more of the indications in
Table I might be treated with long-term warfarin therapy
sufficient to prolong the prothrombin time to 1.5 to 2.0
times control, using rabbit brain thromboplastin (standard-
ized INR = 3.0 to 4.5), whereas lower risk patients (in-
dications I, 2 or 3 in Table 1) might be treated with long-
term warfarin therapy sufficient to prolong the prothrombin
time to only 1.2 to 1.5 times control, using rabbit brain
thromboplastin (standarized INR = 2.0 to 3.0).
Mitral valve disease. There are no prospective random-
ized trials that tested the effectiveness of orally administered
anticoagulant agents in the primary prevention of embolism
in patients with mitral valve disease. There have been many
level IV studies confirming the effectiveness of anticoag-
ulants in preventing recurrence of thromboembolism
(5,6,39-41) and, thus, a primary prevention trial would be
untenable. Prophylactic anticoagulation is advised for pa-
tients who are at risk for thromboembolism (Table I). The
older patient with more marked disease is also at greater
risk, in part, because of one or more of the risk factors
listed in Table I. However, patients without risk factors for
thromboembolism have no greater risk from thromboem-
bolism than from severe hemorrhage complicating antico-
agulant treatment (42). Anticoagulant therapy is inappro-
priate in these low risk patients. Although the platelet inhibitor
sulfinpyrazone may be beneficial in the prevention of sys-
temic embolism (43), two-thirds of the patients from this
study also received concomitant anticoagulant therapy and,
thus, sulfinpyrazone was not fully tested alone.
Mitral valve prolapse. Because the incidence of em-
bolic events in patients with mitral valve prolapse is ex-
tremely small, prophylactic antithrombotic therapy is not
warranted unless risk factors are present (Table I). Because
valvular thrombi are probably the most frequent cause of
systemic embolism, and because the ischemic events as-
sociated with mitral valve prolapse are usually small in the
absence of atrial fibrillation, initial treatment after a mild
or transient embolic event with a platelet inhibitor such as
aspirin (325 mg daily) appears rational (16,44-46) if in-
dications 1 to 3 in Table 1 are not present (if these indications
are present, anticoagulation would be indicated). If a cere-
bral ischemic event is large or recurs during antiplatelet
therapy, reevaluation for other causes of stroke is warranted,
and the use of long-term anticoagulant therapy also appears
rational. For patients with significant mitral incompetence
secondary to valvular prolapse, anticoagulation should be
considered in the same way as just discussed and as outlined
in Table I.
Aortic valve disease. The small number of patients with
aortic valve disease who have the risk factors for throm-
44B CHESEBRO ET AL
ANTITHROMBOTIC THERAPY IN VALVULAR HEART DISEASE
lACC Vol 8. No 6
December 1986.-l1 B-56B
boembolism (Table 1) should receive oral anticoagulants.
However, most emboli in patients with aortic valve disease
are calcareous, and because no medical therapy exists to
prevent these ischemic episodes, recurrent embolism may
justify aortic valve replacement.
Because disrupted valvular endothelium and turbulence
across a mildly abnormal aortic valve (including bicuspid
valves) can stimulate platelet deposition on the valve (27),
some of the neurologic symptoms seen in patients with aortic
stenosis may be the result of platelet emboli. However, this
hypothesis is still untested, and to date there are no data to
support the use of platelet inhibitor therapy in these patients.
Prosthetic Valve Replacement
Incidence and Mechanism
Patients who have had prosthetic cardiac valve replace-
ment have a long-term risk of arterial thromboembolism.
The proportion of patients free of thromboembolism after
prosthetic valve replacement decreases throughout the first
and second decades after operation in spite of administration
of oral anticoagulant therapy. In patients with a Starr-
Edwards prosthetic valve, only 66% were free of throm-
boembolism at 10 years and only 58% were free of throm-
boembolism 15 years after operation (47).
Platelet deposition and survival time. The pathologic
events leading to thromboembolism begin during surgery.
The damaged perivalvular tissue and the prosthetic materials
activate platelets as soon as blood starts flowing across the
valve, leading to immediate platelet deposition. A Dacron
sewing ring is common to all prosthetic valves, both me-
chanical and bioprosthetic. Platelet deposition on this ring
can be imaged using indium-Ill-labeled platelets within
the first 24 hours after operation when either a mechanical
or a bioprosthetic valve is placed in an experimental animal
(Fig. I) (48,49). In addition, the prosthetic materials acti-
vate factor XII, and platelet activation also activates the
clotting system (50). Platelet thrombi are stabilized by fi-
brin, especially when there is stasis and decreased blood
flow such as in the left atrium during atrial fibrillation or
during low output states with left ventricular dysfunction.
Thus, when thromboembolic rates are very high, a rational
approach appears to be a combination of therapy with an
anticoagulant plus a platelet inhibitor.
Shortened platelet survival, indicating an increased risk
of thromboembolism, is frequently present in patients with
a prosthetic heart valve (51-53). The degree of shortening
of the platelet survival is, in part, dependent on the surface
area of the heart valve and correlates with the risk of arterial
embolism (51,53). The surface area of the aortic valve is
smaller than that of the mitral valve and. of course, the
combination of the two valves has a greater surface area
(51). Patients with shortened platelet survival appear to be
Figure 1. Scintigram of thorax of an intact dog, left anterior
oblique view, 25 hours after operation and 24 hours after intra-
venous administration of indium-Ill-labeled platelets, showing
radioactivity of platelets deposited on Dacron sewing ring and
perivascular tissue after mitral valve replacement with a Bjork-
Shiley valve. Similar in vivo imaging of acute deposition of
indium-Ill-labeled platelets can be done immediately after bio-
prosthetic heart valve replacement. (Reprinted from Dewanjee MK,
et al. [49J by permission of Mayo Clinic Proceedings.)
at an increased risk of thromboembolism because this re-
flects continuing platelet aggregation and deaggregation both
before and after the clinical thromboembolic event (51,53,54).
The ability to correct shortened platelet survival with platelet
inhibitor therapy appears to predict the effectiveness of this
therapy in preventing thromboembolism in an individual or
groups of patients (51,53).
Clinical manifestations. The predominant clinical man-
ifestations of arterial thromboembolism are in the brain and
retinae. Although only 15% of the cardiac output goes to
the brain, ischemia or necrosis is very sensitively detected
in the cerebral and retinal circulation. Thus, 85% of arterial
thromboemboli are clinically manifest in the brain or retina:
approximately 50% of these emboli lead to permanent neu-
rologic or visual deficit and 10% lead to death (47). Of the
remaining 15% of emboli, only about 5 to 10% are manifest
in the peripheral arterial circulation and about 5 to 10% are
clinically manifest in the coronary circulation as a myo-
cardial infarction (47). From pathologic studies, it appears
that only a fraction of these peripheral and coronary emboli
that are present at postmortem examination result in clinical
manifestations. About 25% of patients who have a throm-
boembolic event will have more than one such event (47).
Risk Factors for Systemic Embolism (Table 2)
Patients with aortic valve replacement are usually at a
lower risk of thromboembolism than are those with mitral
valve replacement; combined aortic and mitral valve re-
placement usually produces the highest risk of thromboem-
bolism. This may be related, in part, to the increased surface
area of the prosthetic heart valves (51) as well as to more
advanced heart disease, with a greater potential for left
lACC Vol 8, No 6
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Table 2. Risk Factors for Thromboembolism in
Patients With Prosthetic Heart Valves*
PatIent factors
Valve 10catIont
Adequacy of antIcoagulatIon
Atnal fibrillation
SinUS rhythm with large left atnum (>50 mm)
PrevIOus thromboembolism
Severe left ventncular dysfunction
Year of operation (operation is performed earlier In
course of disease today)
Valve factors
DeSign: less turbulence and stasIs
Matenals: less thrombogemc
*CumulatJve inCidence increases directly with time
after operation. t Aortic, mitral or combined valve re-
placement.
ventricular dysfunction and atrial fibrillation in patients with
mitral valve or combined valve replacemenL
Adequacy of anticoagulation. Adequate anticoagula-
tion is important in preventing thromboembolism (47,55-59).
In most studies, adequacy of anticoagulation was defined
as a prothrombin ratio of 1.5 to 2.5 times control and by
the proportion of prothrombin times within the therapeutic
range, In one study (47), anticoagulation was defined as
adequate if the prothrombin times were, on the average,
equal to or greater than 1,5 times the control valve for the
preceding year, Using these criteria, a difference was found
in the importance of anticoagulation between the two valve
positions; for the mitral Starr-Edwards valve, the throm-
boembolic event rate (including recurrences) in patients with
adequate anticoagulation was less than half that of patients
in whom anticoagulation was inadequate (Table 3). There
was no difference between these groups for aortic valve
replacemenL This may be, in part, because of the high flow
across the aortic valve, which can predispose to thrombi
consisting predominantly of platelets compared with the
fibrin thrombi that appear to be more prominent with mitral
Table 3. Starr-Edwards Prosthesis: Systemic
Embolism and Adequacy of Anticoagulation*
% Events/Patient-Year
Anticoagulation MVR AVR
Adequate* 6.4 6.5
Inadequate 14.2 8.5
p <0.01 NS
*Rabbit brain thromboplastin ratio of 1.5 to 2.5 (in-
ternational nonnalized ratio = 3.0 to 7.5); Inadequate
if less than the lower ratIos. AVR = aortic valve re-
placement; MVR = mitral valve replacement NS =
not significant. (Reproduced from Fuster V, et al. [47],
with pennission from the American Heart Association,
Inc.)
valve replacemenL When a thromboembolic event occurred,
the prothrombin time drawn at the time of the event was
less than 1.5 times control (international normalized ratio
[INR] > 3,0) approximately 50% of the time (55,59), Fur-
ther analysis showed that in all patients without a throm-
boembolic event, the prothrombin time was less than 1.5
times control (INR < 3,0) in 30% of all determinations,
whereas in the group with a thromboembolic event, 41 %
of the prothrombin times were too low (p < 0.05).
Atrial fibrillation. This was not an independent risk
factor for thromboembolism in patients who had valve re-
placement during the 1960s (47,55,57), However, because
valve replacement was deferred until the later stages of the
valvular disease at that time, nearly all of the patients with
mitral valve replacement had atrial fibrillation. More recent
studies (60,61) have found that atrial arrhythmias increase
the risk of thromboembolism. Several studies (62-67) have
shown that embolism from bioprosthetic heart valves occurs
mainly in patients with atrial fibrillation. For this reason,
patients with a bioprosthetic heart valve and chronic atrial
fibrillation should receive long-term anticoagulation, In studies
where atrial fibrillation was not found to be a risk factor for
thromboembolism, the method for assessing atrial fibrilla-
tion should always be addressed because patients who have
atrial fibrillation for less than 1 year before operation are
more likely to experience conversion to sinus rhythm after
the operation, especially after hospital discharge. Thus, in
one recent study (68), up to 33% of patients with atrial
fibrillation before operation had conversion to sinus rhythm
after operation. Age may predispose to atrial fibrillation after
operation, even in patients with aortic valve replacement;
in a recent study (69), 61 % of patients older than 70 years
of age had at least transient atrial fibrillation after aortic
valve replacemenL Thus, attempts to restore and maintain
sinus rhythm after operation are justified. Earlier operation
to prevent permanent chronic atrial fibrillation may be jus-
tified, especially if reconstructive techniques are used (70-73).
Furthermore, because patients with a large left atrium are
at risk of developing atrial fibrillation, they too should be
considered at particular risk of thromboembolism,
Factors reducing risk of thromboembolism. The risk
of thromboembolism after prosthetic cardiac valve replace-
ment is lower today than it was 10 years ago (74), in part,
as a result of fewer patient risk factors. Today, patients are
undergoing valve replacement or repair at an earlier stage
of their disease and, thus, have better left ventricular func-
tion, a smaller left atrium and a lower incidence of atrial
fibrillation. In addition, there are valve factors that have
also contributed to lower rates of embolization in more
recent years. Valve design has improved in that: 1) flow
across valves is less turbulent and there is less stasis im-
mediately adjacent to the valves, and 2) improved materials
in modem valves are less thrombogenic and also contribute
to lower rates of thromboembolism.
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Complete Reporting of Thromboembolism
For a complete report of thromboembolism in prosthetic
cardiac valve replacement, 10 factors need to be addressed,
as discussed in a recent editorial (75) and amplified and
emphasized here. These factors are important for providing
valid information on the risk of thromboembolism after val-
vular heart operations and facilitating a comparison of stud-
ies at different centers. These factors include:
1) Adequacy of follow-up. The percent of patients lost
to follow-up study and the duration of follow-up should be
stated.
2) Proportion of patients responding to specific ques-
tions. The proportion of patients who responded to specif-
ically defined questions regarding the possibility of whether
they experienced thromboembolism should be stated.
3) Specific definition of thromboembolism. A specific
definition of thromboembolism should be provided. The
clinical diagnosis of brain or retinal embolism of cardiac
origin is based on a constellation of findings, none of which
is diagnostic by itself (18). An inclusive and succinct def-
inition is a focal and maximal neurologic deficit of sudden
onset (motor or visual) in an awake, usually active patient
that usually involves the cerebral cortex (middle cerebral
artery or its branches), cerebellum or retina (1,8,76). A
progressive or stuttering course may occur in approximately
10% of patients, and is probably due to distal embolization
of embolic fragments (18,76-78). Vertebrobasilar or an-
terior cerebral artery emboli are much less frequent, and
each accounts for no more than 10% of embolic sites. Car-
diogenic emboli to the basilar artery usually lodge at its
distal bifurcation, producing ischemia to both occipital lobes
due to obstruction of the origin of the posterior cerebral
arteries (79). Multifocal neurologic findings or ischemic
events in other vascular territories are also characteristic. A
systemic embolus to the extremities is defined by the sudden
onset of symptoms of occlusion (pain, pallor, paralysis),
loss of distal pulses and angiographic or operative findings.
A coronary embolus, manifested as myocardial infarction
(symptoms, electrocardiographic changes and elevated car-
diac enzymes), is diagnosed only when the coronary arteries
are known to have been normal or the patient was younger
than 40 years of age without coronary risk factors. Other
systemic emboli must be defined by angiographic or surgical
evidence.
4) Categorization of thromboembolism. Emboli are usu-
ally categorized as a) minor or transient, b) major or as-
sociated with a permanent residual neurologic deficit, myo-
cardial infarction or the requirement for operation or other
significant therapeutic modality, or c) lethal. Emboli to the
brain or retina cause a residual deficit in about 50% and are
lethal in about 10% (47).
5) Actuarial rate given. Information regarding the ac-
tuarially evaluated incidence of thromboembolism should
be provided in either tabular or graphic form or in the text.
Data provided to 4 to 5 years of follow-up or beyond are
preferable.
6) Linearized rate given or calculable. A linearized rate
for the appearance of thromboembolism should be provided
or sufficient data given to allow the reader to calculate this
information.
7) List valve thromboses. A specific list of the incidence
of valve thrombosis should be given so as to indicate the
propensity for this deadly occurrence, which is also an in-
dication of the durability of the valve.
8) Duration of anticoagulation. The percent of patients
who received anticoagulation for specified intervals of time
should be stated.
9) Adequacy of control. The following should be stated
about the measurement of the prothrombin time: the type
of thromboplastin used (for example, rabbit brain, Sim-
plastin), its international sensitivity index and the therapeu-
tic range defined by the prothrombin time ratio (for example,
1.5 to 2.0 times control) and equivalent international nor-
malized ratio (for example, 3.0 to 4.5). This should be
quoted to facilitate reference to the World Health Organi-
zation standardized ratio determined using human brain
thromboplastin. The use of human brain thromboplastin gives
higher values than does rabbit brain thromboplastin (38) at
a given degree of anticoagulation.
10) Analysis of effect of anticoagulation. The effect of
the adequacy of anticoagulation on the incidence of throm-
boembolism should be reported. This can be done by re-
porting the incidence of thromboembolism with and without
anticoagulant therapy and the incidence in patients who have
a certain proportion of prothrombin times (such as 70 or
80% or more) within therapeutic range versus those with
less than this proportion in range either overall or on a yearly
basis. Additionally, the proportion of prothrombin times
within therapeutic range and the proportion too low at the
time of a thromboembolic event should be reported.
Bleeding events. The same type of reporting (as in factors
5, 6 and 10) is appropriate for the incidence of bleeding
events and the relation of the event to adequacy of anti-
coagulation. A major bleeding event is usually defined as
an intracranial bleed or one that requires hospitalization or
blood transfusion.
Mechanical Prosthetic Cardiac Valves
Incidence of thromboembolism. Recent reports
(68,72,80-88) of mechanical valve replacement are sum-
marized in Table 4. Although the Starr-Edwards valve is
thought to have the highest incidence of thromboembolism,
the incidence varied in different studies and did not differ
greatly overall from that described in reports of replacement
with the Bjork-Shiley valve. The main difference between
these two mechanical valves was the higher incidence of
valve thrombosis with the Bjork-Shiley valve.
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Year of
Bleed (%/yr) OperatIOn
2.4/\.4 1973-1977
1.4/1.1 1974-1978
2.0/2.2 1973-1977
2.4/1.1 1974-1977
\.812.9 1974-1982
-/3.0 1973-1978
\.2/1 7 1972-1983
26/2.8 1978-1980
7.9 1979-1981
1978-1982
Study (Reference)lYear
Starr-Edwards valve
Murphy et at. (80)
1983
Perier et at. (72,81)
1985/1984
Bjork-Shiley valve
Murphy et at. (80)
1983
Perier et at. (72,81)
1985/1984
Horstkotte et at. (82)
1983
Marshall et at. (83)
1983
Cohn et at. (68,84)
1984/1985
St. Jude valve
Horstkotte et at. (82)
1983
Douglas et at. (85)
1985
Chaux et at. (86)
(If antIplatelet Rx
only)
1984
Baudet et at. (87)
(if no ACRx)
1985
Arom et at. (88)
1985
Pt (no.)
467/342
100/100
110/105
100/100
393/442
-/357
294/178t
147/167
67/-
73/90
471/95
65/10
3491234
TE (%/yr)
2.0/3.4
2.4/4.3
1.2/2.2
20/4.6
\.9/2.8*
-/3.7
\.9/4.6
0.73/0.93*
2.8/-
1.3/2.3:1:
0.34/0.45§
6.1/16.7
0.7/2.2
%
Throm (%/yr)
<0.1/<0.1
0.5/0 I
0.5/\.6
0.2/1 1
02/0.3
-/0.7
0.3/0.5
0/0
0.3/0
0/0
6.2/5.6
0/0
0.65
4.6/2.2
1978-1983
1977-1983
*Exc1udes transient cerebral ischemic attacks. tMitral valve replacement (102 Bjork-Shiley, 34 Beall and 42 Harken valves). :1:3.7% per year for 35
patients on oral anticoagulant therapy with mitral and aortic valve replacement. §Thromboembohsm undefined ACRx = oral anticoagulant therapy;
AVRlMVR = aortic valve replacement/mitral valve replacement (the values in each column compare the number or percent of cases III each group);
Bleed = bleeding episodes; no. = number; Pt = patient; Rx = therapy; TE = thromboembohsm. Throm = thrombosIs of valve.
Reports of patients with the St. Jude valve, especially
the study (82) that compared the Bjork-Shiley valve with
the St. Jude valve, suggested a lower incidence of throm-
boembolism in patients with the St. Jude valve. However,
more recent years of operation for patients with the St. Jude
valve raise a question of comparability of these groups. The
exclusion of transient cerebral ischemic attacks from the
rates of thromboembolism, as in one study (82), decreases
the reported incidence of embolism by as much as 50%. In
another study (79), the definition of thromboembolism was
not given. The therapeutic range for warfarin therapy was
seldom reported. The adequacy of anticoagulation was not
assessed except for patients with or without anticoagulant
therapy in two studies (86,87). In our prospective study (59)
of mechanical prosthetic valve replacement from 1979 to
1981 that involved mainly Starr-Edwards and Bjork-Shiley
valves and a small number of St. Jude valves, the incidence
of thromboembolism was low (1.2 to 1.8% per year) and
did not differ among any of these types of valves. Two other
studies (85,86) suggested comparable rates of thromboem-
bolism with the Bjork-Shiley and Starr-Edwards valves. It
is clear that even for the St. Jude valve, oral anticoagulation
is essential and platelet inhibitor therapy alone is ineffective
for the prevention of thromboembolism and valve throm-
bosis (86,87).
Prospective intervention trials. Prospective random-
ized trials of oral anticoagulant therapy with and without a
platelet inhibitor have been conducted because of the chronic
risk of thromboembolism noted in patients with a mechan-
ical prosthetic heart valve treated with oral anticoagulant
therapy alone (Tables 5 and 6). Therapy with an oral an-
ticoagulant plus dipyridamole for the prevention of throm-
boembolism has just been approved by the U.S. Food and
Drug Administration because this therapy decreased the in-
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Table 5. Antithrombotic Therapy in Patients With Mechanical Prosthetic Heart Valves*
Follow-Up Treatment Do,e Patient, Thromboembolic
Study (Reference) Methods (yr) Group (mg/day) (no.) Event; (%/yr)
Sullivan et aL (89) Prospective. A/C + placebo 84 14
randomized A/C + D (400) 79 I
Kasahara (90) Prospective. I to 3 A/C 39 21
randomized (mean 30 mol A/C + D (400) 40 5
Groupe PACTE (91) Prospective. A/C 154 5
randomized A/C + D (375) 136 3
Rajah et aL (92) Prospective. I to 2 A/C 87 13
randomized A/C + D (300) 78 4
Dale et aL (93) Prospective. A/C + placebo 38 9
randomized. A/C + ASA (1.000) 39 2
blind ASA (1.000) 77 15
Altman et aL (94) Prospective. 2 A/C 65 20
randomized A/C + ASA (500) 57 5
*A/C = anticoagulant; ASA = aspirin; D = dipyndamole. (Reproduced from Fuster V. Chesebro lH. Anlithrombotic therapy: role of platelet-
mhlbltor drugs: management of arterial thromboembolic and atherosclerotic disease. Mayo Clin Proc 1981; 56:265-73. by pennis'lOn of the Mayo
FoundatIOn. )
cidence of thromboembolism when compared with oral an-
ticoagulation alone in five trials (one level I study [89] and
four level II studies [59,90-92]. A dipyridamole dosage of
300 to 400 mg/day or 5 to 6 mg/kg body weight per day
was chosen in these studies because this dosage maximally
prolonged a shortened platelet survival in patients with pros-
thetic heart valve replacement (51,54). The addition of as-
pirin to an oral anticoagulant in two trials (93,94) produced
a reduction in thromboembolism. However, the incidence
of gastrointestinal bleeding was significantly increased with
an aspirin dosage of 1 g/day (93), and the incidence of
melena was slightly increased (7% of patients receiving
aspirin versus 2% of patients receiving anticoagulant alone)
with aspirin, 500 mg/day (administered as 250 mg twice
daily) (94).
Comparison among oral anticoagulants, dipyridamole
and aspirin. Because of the suggestion that aspirin admin-
istered at 250 mg twice daily might be of equal therapeutic
efficacy and safety as dipyridamole at 400 mg/day, we com-
pared the efficacy and safety of three drug regimens for the
prevention of thromboembolism in 534 patients who had
mechanical prosthetic cardiac valve replacement between
1979 and 1981 (59): warfarin alone, warfarin plus dipyr-
idamole (400 mg/day) and warfarin plus aspirin (500
mg/day) (Table 6). By August 1981, after 1,319 patient-
years of follow-up, major bleeding necessitating blood
transfusion or hospitalization was excessive in the group
receiving warfarin plus aspirin, but not in the groups re-
ceiving warfarin plus dipyridamole or warfarin alone. Thus,
in August 1981, we discontinued the use of aspirin with
Table 6. Thromboembolism and Episodes of Bleeding*
Treatment
Thromboembolism Bleeding
Group No. Pt-yr no. (%) %/yr Pro T t GI Cerebral Other n (%) %/yr Pro T t
W + ASA 170 386 7(4) 1.8 2/7 15 5 3 23(14) 6.6:1: 8/23
W+D 181 427 2(1) 0.5 2/2 4 0 3 7(4) 1.6 3/7
W 183 506 6(4) 1.2 3/6 I 3 5 9(5) 1.8 4/9
Total 534 1.319 15 7/15t 20 9 II 39 15/39
*Adjustment for type and locatIOn of valve resulted in only tnvial changes. All thromboemboli were located in the bram or retinae. including one
associated aortic valve thrombosis. and all were durmg the first year of follow-up. except for two m ASA group (year 2) and one in control group (year
3). tUnknown in two patients. :l:p < 0.001 compared with each of the other two groups. ASA = aspirin; D = dipyndamole; GI = gastrointestinal;
Pro T t = prothrombin timelcontrol < 1.5; Pro T t = prothrombm limelcontrol >2.5; Pt-yr = patient-years; W = warfann. (Reproduced from
Chesebro lH. et aL [59], by pennission of Techmcal Publishmg.)
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warfnrin, and concluded that the addition of aspirin to war-
farin therapy at this dosage was contraindicated. Most of
the bleeding was gastrointestinal. In addition, intracerebral
bleeding occurred in both the aspirin group and the warfarin
only group, but did not occur in the warfarin plus dipyr-
idamole group, suggesting the possibility that thromboem-
bolism, which was decreased in the warfarin plus dipyrid-
amole group, may predispose to secondary intracerebral
bleeding. The incidence of thromboembolism was relatively
low in all groups, as is characteristic of mechanical pros-
thetic valve replacement in more recent years. There was a
greater reduction of thromboembolism in patients receiving
warfarin plus dipyridamole (approximately a 50% reduction)
compared with those receiving warfarin plus dipyridamole
(approximately a 50% reduction) compared with those re-
ceiving warfarin alone or warfarin plus aspirin, but these
differences were not statistically significant because of the
small total number of embolic events. Further follow-up
study in 1984 showed a thromboembolic rate of 1.8% per
year in the warfarin only group compared with 1.0% per
year in the warfarin plus dipyridamole group, again an ap-
proximately 50% reduction in the rate of thromboembolism,
which remained low in all groups, but this difference was
Table 7. Thromboembolism in BlOprosthetic Valve Replacement
not statistically significant because of the low overall rate
of embolism. This study is the fourth level II study providing
evidence for a reduction in thromboembolism when dipyr-
idamole is added to anticoagulant therapy.
Bioprosthetic Cardiac Valves
Incidence of thromboembolism. Thromboembolism after
bioprosthetic valve replacement is less frequent than after
mechanical valve replacement, but the incidence is quite
variable and, in part, might depend on the selection of
patients with various risk factors for thromboembolism and
whether patients received anticoagulant treatment early after
operation. Recent reports (68,72,81,83-85,95-99) on por-
cine valves (Hancock and Carpentier-Edwards) and a bovine
pericardial valve (Ionescu-Shiley) showed rates of throm-
boembolism that were quite variable (Table 7). The results
of one study (95) comparing the porcine and bovine peri-
cardial valves, which showed a much lower rate of throm-
boembolism for the bovine pericardial valve, might be ex-
plained, in part, by the younger mean age (12 years) of
valves in the latter group; in addition, the distribution of
patients with the two different valve types among the four
AVR/MVR
Study Chrome
%/yr
Year of
(Reference)/Year Pt (no.) ACRx (%) TE Throm Bleed Operallon
Porcine valve
Marshall et al. (83) -/96 13* -/4.4 -/0.3 -/0.3 1974-1978
1983
Pener et al. (72.81) 1001100 21/74* 06/0.9 0/0 0.1/03 1974-1978
1985/1984
MV repair 100 50* 06 0 -/0.3 1974-1977
Gonzales-Lavin et al. (95) -1206 51* -/4.6 -/0 -/2.5 1974-1982
1984
Douglas et al. (85) 120/- 16*t 19/- 0/- 24/- 1979-1981
1985
JamIeson et al. (96) 155/154 IO/45't I 111.7 0/0 0.1 1976-1983
1984
Cohn et al (68.84) 663/528 AF I 7/2.4 0.1/0 0.2/0.4 1972-1983
198411985
Zussa et al. (97) 287/506 AF* 05/3.2 0.3 0.8 1974-1980
1985
Bovine pericardial valve
Gonzales-Lavin et al. (95) -/322 0* -/0.4 -/0 -/0.6 1974-1982
1984
Brms et al (98) 292/140 51 1.4/40 () 1977-1983
1985
Reul et al. (99) 1,427/982 30/63 1.4/28 -/- -/- 1978-1983
1985
AVR + MVR 258 70 2.0 -/- -/-
*Short-term oral anticoagulant therapy In all for 2 to 6 months t Additional 47% received antiplatelet agents. :j:Chromc anticoagulant therapy if atrial
fibrillation. large left atrium. Intracardiac thrombus. §Short-term anllcoagulant therapy in all for 6 weeki>. lIn remainder. 5 to 7 days "minimal
heparimzallon." then aspirin 975 mg + dipyndamole 150 mg/day. Abbreviations as In Table 4.
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clinical centers pooling their results was not stated. Another
center with low rates of thromboembolism in patients with
porcine valve replacement (72,81) usually selects patients
for bioprosthetic valve replacement who have sinus rhythm
or who have had atrial fibrillation for less than I year. In
addition, this same center starts heparin therapy 6 hours
after operation (intravenously until the chest tubes are out)
and continues it for 10 days (subcutaneously, maintaining
the partial thromboplastin time at 1.5 to 2 times normal)
while starting warfarin therapy, which is continued for 3
months. Overall, the lower thrombogenicity of the bio-
prosthetic valve is evident in the lower rates of thromboem-
bolism in the absence of anticoagulation compared with the
very high rates with mechanical valves when no anticoag-
ulation is given (Tables 4 and 7).
Mayo Clinic experience. From 1971 through 1981, bio-
prosthetic cardiac valve replacement at the Mayo Clinic was
performed in the aortic position in 340 patients and in the
mitral position in 287 patients (59). The type of valve used
was the Hancock in 57% of these patients, Carpentier-Ed-
wards in 20% and Ionescu-Shiley in 23%. Only 27% of
patients with aortic valve replacement, but 82% of patients
with mitral valve replacement, were discharged from the
hospital on anticoagulant therapy. The three factors most
predictive of higher thromboembolic risk were: I) valve
replacement in the mitral position, 2) the early time period
(especially the first 10 days and 3 months) after operation,
and 3) the absence of warfarin therapy. Approximately 25%
of all embolic events occurred within the first 3 months.
The linearized rates of thromboembolism (percent per year)
for aortic and mitral valve replacement, respectively, were
45 and 83% during the first 10 days after operation, 2.9 and
9.4% during days II to 90 after operation and 1.8 and 2.7%
per year beyond 3 months after operation. These high rates
of thromboembolism, especially early after operation, sug-
gest that more potent antithrombotic therapy is necessary in
this period.
A comparison of the incidence of thromboembolism with
and without warfarin therapy showed that for patients with
mitral valve replacement with warfarin therapy, there were
1.5 events per year (3 events during 207 exposure years),
but without warfarin therapy there were 3.8 events per year
(36 events during 946 patient-exposure years, p = 0.07).
For aortic valve replacement in patients with warfarin ther-
apy, there were 1.1 events per year (I event during 90
exposure years) and without warfarin therapy there were
2.2 events per year (26 events during 1,189 patient-exposure
years, not significantly different). Thus, warfarin therapy
appeared especially important for patients with mitral valve
replacement and was probably most critical early after op-
eration (during the first 3 months) (100).
Other intervention trials. No prospective randomized
intervention trials for prevention of thromboembolism have
been carried out in patients with bioprosthetic heart valves.
One level IV study (10 I) (in patients with a relatively low
mean age of 44 years, who had mitral valve replacement
with a porcine bioprosthesis and had atrial fibrillation) com-
pared the group of patients who had valve replacement from
1975 to 1979 and were treated with I g of aspirin per day,
starting on the second postoperative day (incidence of em-
bolism of 1.3% per patient-year), with a second group of
patients who had valve replacement since 1979 and were
treated wtih 0.5 g of aspirin every other day, starting on
the first postoperative day (incidence of embolism of 0.3%
per year). There was no control group in this level IV non-
randomized study, which suggested that aspirin in low dose
may be of benefit in patients with bioprosthetic heart valve
replacement. It is not clear from the report whether only
major embolism or major plus minor (transient ischemia)
embolism was considered in determining the thrombo-
embolic incidence.
Current Recommendations
Recommendations for antithrombotic therapy for pros-
thetic cardiac valve replacement are outlined in Table 8.
Because platelet thrombus deposition begins as soon as blood
begins flowing across the prosthetic valve and can be imaged
within hours after operation (Fig. I) (48,49), antithrombotic
therapy would ideally be started before operation, but such
studies have not yet been performed. Thus, we suggest
following the practice of starting intravenous heparin 6 hours
after the operation in all patients for all types of prosthetic
heart valves (approximately 600 to 700 USP Ulhour to main-
tain the activated partial thromboplastin time at the upper
limit of normal) and continuing until the chest tubes are
removed. Then subcutaneous heparin, using 10,000 units
every 12 hours, is continued (adjusting to maintain the ac-
tivated partial thromboplastin time at 1.5 to 2 times the
upper limit of normal) until the time of hospital dismissal
(grade C recommendation).
Patients with mechanical prosthetic cardiac valves.
Warfarin should be started as soon as possible after operation
and administered at a dose sufficient to prolong the pro-
thrombin time to 1.5 to 2.0 times control, using rabbit brain
thromboplastin (standardized international normalized ra-
tio = 3.0 to 4.5). Because of the very high rates of throm-
boembolism with inadequate anticoagulation (which may
occur accidently in 30% of prothrombin time measurements
[59]), the continued long-term risk of thromboembolism and
the lower risk of thromboembolism when dipyridamole is
added to anticoagulant therapy (Tables 5 and 6), dipyrid-
amole (350 to 400 mg/day or 5 to 6 mg/kg body weight per
day, for example, 75 mg three times daily with meals and
150 mg at bedtime) should be added to warfarin therapy
(grade A recommendation).
Approximately 5 to 10% of patients have intolerance to
dipyridamole due to gastrointestinal upset or headache.
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Table 8. Antithrombotic Therapy for Prosthetic Heart Valves: Current Recommendations
In all patients, begin intravenous heparin* starting 6 hours after operation and continue until chest tubes are
removed. Then use subcutaneous heparl1l, starting with 10,000 U every 12 hours, t for the duration of hos-
pitalization.
Valve
Mechanical
Bioprosthetic
Situation
Routine
DIp side effects
ACRx problem, (bleedmg)
Recurrent embolism
AVR routme
MVR routme
If LA >55 mm or AF
Therapy
Warfarmt + DIp 400 rug/day
Warfannt + Sulf 800 rug/day
I) t Warfann§ + Dip 400 mg/day
2) Dip 400 mg/day + Sulf 800 mg/day
Consider reoperation
Subcutaneous hepann for 7 to 10 day"
then ASA 80 mg/day
Subcutaneous hepann, warfarint for 3
mo, then ASA 80 mg/day
Warfannt long-term
*Approxlmately 600 to 700 USP Ulhom, sufficient to maintain an actIvated partial thromboplastin time at
the upper limit of normal. t Adjust dose to prolong the activated partial thromboplastin tIme to 1.5 to 2 times
the upper limit of normal; tProlong prothrombin time to 1.5 to 2 tImes control, using rabbit brain thrombopla,tm
<standardized mtemational normalized ratio = 3.0 to 4.5); §Prolong prothrombin time to 1.2 to 1.5 tImes
control, using rabbit bram thromboplastin <standardized mtematlonal normalized ratIo = 2.0 to 3.0)
ACRx = anticoagulant therapy; AF = atrial fibrillation; ASA = aspirin; AVR = aortic valve replacement;
Dip = dlpyndamole; LA = left atrium; MVR = mitral valve replacement: Sulf = sulfinpyrazine.
Gastrointestinal upset may be diminished by giving the di-
pyridamole with food, and the vasodilator effects (head-
aches) may also be diminished by slowing the absorption
with food or can be reversed by adding aminophylline (50
to 100 mg with each dose of dipyridamole) (102).
In patients who continue to be intolerant ofdipyridamole
in spite of these measures, we recommend the addition of
sulfinpyrazone (800 mg/day) to warfarin therapy. This grade
C recommendation is based on one level III study (53); no
randomized prospective trial using sulfinpyrazone has been
done. The uncontrolled study (53) suggested that sulfin-
pyrazone is effective in certain patients, mainly in those in
whom it prolongs the shortened platelet survival. The pro-
thrombin time may be more prolonged by the addition of
sulfinpyrazone and, thus, the prothrombin time should be
checked more frequently after initiating therapy with sul-
finpyrazone. Aspirin is contraindicated for patients on war-
farin therapy because of bleeding (59). Acetaminophen or
sodium salicylate should be used for pyrexia or analgesia.
In patients on anticoagulant therapy who have a bleeding
problem when the prothrombin time is not prolonged beyond
2 times control (rabbit brain thromboplastin, INR = 4.5),
we recommend evaluation for a secondary cause of bleeding
(such as an underlying tumor) and lower doses of warfarin
(prothrombin time 1.2 to 1.5 times control, INR = 2.0 to
3.0) in combination with dipyridamole.
For patients who are unable to take anticoagulant ther-
apy. we recommend a trial of dipyridamole (400 mg/day as
outlined) combined with sulfinpyrazone at 200 mg four times
daily as empiric temporary therapy (using two platelet in-
hibitors that are most effective against thrombosis on pros-
thetic materials); this antiplatelet therapy is not recom-
mended indefinitely because antiplatelet therapy does not
appear to be effective in the long term in patients with
mechanical prosthetic cardiac valves (Table 4). Any patient
who has recurrent thromboembolism in spite of adequate
antithrombotic therapy should be seriously considered as a
candidate for repeat valve replacement.
Patients with bioprosthetic heart valve replacement
(Table 8). Intravenous heparin should also be initiated 6
hours after operation, switched to subcutaneous heparin after
the chest tubes are removed (starting with 10,000 units every
12 hours) and continued for the duration of hospitalization.
For patients with aortic valve replacement, empiric therapy
with aspirin, 80 mg/day (1 baby aspirin tablet), should be
continued indefinitely (grade C recommendation) as extra-
polated from one level IV study (101). An alternative is the
administration of warfarin for 3 months before starting the
empiric aspirin, which would be used indefinitely for the
small (0.6 to 1.9% per year) but definite chronic throm-
boembolic risk. Prospective, randomized. controlled trials
using aspirin therapy need to be conducted.
For patients who have bioprosthetic mitral valve re-
placement, warfarin therapy should be initiated as soon as
possible after operation (while the patient is receiving sub-
cutaneous heparin) to prolong the prothrombin time to 1.5
to 2.0 times control, using rabbit brain thromboplastin (stan-
dardized international normalized ratio = 3.0 to 4.5), while
the thromboembolic risk remains very high during the first
3 months after operation. In patients who have atrial fi-
brillation, an enlarged left atrium or a documented previous
thromboembolism, therapy with warfarin should be contin-
ued indefinitely. The value of aspirin at a dosage of 80
mg/day for long-term therapy in these patients with atrial
52B CHESEBRO ET AL
ANTITHROMBOTIC THERAPY IN VALVULAR HEART DISEASE
lACC Vol 8. No 6
December 1986 41 B-S6B
Table 9. Patient Conditions Can Change Warfarin Dosage
AIC = anllcoagulant therapy; NPO = nothing orally; postop = post-
operatively; J, = decrea~e; i = mcrease: D. = change.
Special Situations
Four situations should be considered in prescribing an-
tithrombotic therapy for patients with prosthetic cardiac valve
replacement.
1) Noncardiac surgery. Temporary discontinuation of
anticoagulation for 7 to 10 days appears to be of minimal
risk for patients undergoing a noncardiac operation (04).
However, to keep this risk to a minimum, we recommend
stopping warfarin 4 to 5 days before operation, continuing
dipyridamole (400 mg/day, or starting if it is not being
administered) and starting a heparin infusion (to mantain
fibrillation needs to be tested prospectively and compared
with warfarin therapy. In patients with sinus rhythm and
without an enlarged left atrium, aspirin, 80 mg/day (1 baby
aspirin tablet), should be given indefinitely after stopping
the warfarin therapy at 3 months after operation, because
of the continued thromboembolic risk in these patients. The
value of long-term aspirin therapy needs to be tested in a
prospective controlled trial.
The prothrombin time should be checked at least every
3 to 4 weeks in patients receiving therapy with warfarin and
more often whenever the prothrombin time is above or below
the therapeutic range or whenever the patient's condition
changes (Table 9). If a drug is added to or deleted from the
patient's therapeutic program, the prothrombin time should
be checked because many drugs can alter it (see partial list
in Table 10). Close monitoring is important because of
spontaneous variability in the degree of anticoagulation in
different patients, the high proportion of patients whose
prothrombin time is not in the therapeutic range (on the
average, 30% of prothrombin times are too low and 5% are
too high) (59) and because of the changes in coagulation
that can be cal./sed by the ingestion of vitamin K-containing
foods such as broccoli. lettuce or other green vegetables
Om).
Increase Dose
Vitamin K
Antacids
Oral contraceptives
Rlfampm
Griseofulvm
Cholestyramine
Barbiturates
Glutethimide
Other sedatives
Chronic alcohol
AntihIstamines
Decrease Dose
Anllbiotics
Cimeltdme
Anabolic steroids
D-Thyroxine
Clofibrate
Sulfinpyrazone
Phenylbutazone
Qumidine
Alcohol abuse
Diuretics
Methyldopa
the activated partial thromboplastin time at 2 times control)
when the prothrombin time decreases to less than 1.5 times
control (using rabbit brain thromboplastin, international nor-
malized ratio < 3.0). The heparin infusion should be con-
tinued until 4 to 5 hours before operation. Subcutaneous
heparin (15,000 units/day given in two or three divided
doses) should be continued during and early after operation,
except in patients undergoing brain or eye operation. War-
farin therapy should be restarted as soon as possible after
operation.
2) Prosthetic valve endocarditis. Of patients with pros-
thetic valve endocarditis who are not receiving anticoagulant
therapy, thromboembolism to the central nervous system
occurs in about 50% (105-107). Three nonrandomized clin-
ical studies (105,106,108) in patients with prosthetic valve
endocarditis who were receiving anticoagulant therapy sug-
gest that this thromboembolic rate can be decreased six- to
ninefold with adequate anticoagulation. However, central
nervous system hemorrhage occurred in 14% of these pa-
tients. The benefits and risks of anticoagulation in patients
with bioprosthetic valve endocarditis are not well defined.
Thus, we advise continuing therapeutic anticoagulation as
indicated for the individual patient and prosthetic valve as
long as there is no clinical or laboratory evidence of intra-
cranial hemorrhage or peptic emboli. Patients should be
switched to a heparin infusion in the hospital for versatility
in case emergency operation is required or a significant
bleeding event occurs.
3) Anticoagulation after a thromboembolic event. The
appropriate time to start anticoagulation after thromboem-
bolism to the brain has been controversial. A second em-
bolism can occur early after the initial event, and immediate
anticoagulation appears rational. However, caution should
be exercised because anecdotal reports and experimental
studies suggest that immediate anticoagulation, especially
in patients with a large embolic infarct, can result in sec-
ondary hemorrhage with increased morbidity. Overall data
Table 10. Drug Interactions Can Change
Warfarin Dosage Owing to Change in Drug
Absorption, Protein Binding, Metabolism
or Excretion
i Vltamm K intake
Leafy green vegetables (broccoli,
lettuce, spinach)
Increase Dose
Grean beans
Cauliflower
Liver
Hypometabolism
(hypothyroidism)
Hereditary re~lstance
Decrease Dose
J, Oral intake (postop)
J, Vitamin K stores (recent
AIC, NPO, antibIOtics)
Liver dbease
Hepatic congestIOn
Renal dIsease (J, or D. albumin)
Malignancy, sepsis
DIarrhea. ~teatorrhea
Hypermetabolism
(hyperthyroidism, fever)
Hereditary J, vitamm K clotting
factor~
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from 15 prospective and retrospective level V studies (18)
suggest that approximately 12% of patients (range 0 to 22)
with aseptic embolism to the brain from a cardiac source
experience a second embolic event within 2 weeks. The
early recurrence appears to be evenly distributed over the
initial 2 weeks at about I% per day.
Immediate anticoagulation with heparin appears to de-
crease the risk ofrecurrent embolism. Thus, in patients who
received anticoagulant agents, there was a reduction in early
recurrent embolism within 14 days to about one-third of
that in patients who did not receive anticoagulants in six
level III and IV studies (18). One level II randomized trial
(109) that involved only 45 patients showed a lower recur-
rence rate in patients who received anticoagulants; one non-
randomized study (110) showed the opposite effect.
There are wide variations in the reported risk of symp-
tomatic brain hemorrhage after immediate anticoagulation
for embolic stroke. One group of studies showed no hem-
orrhagic worsening in 162 patients who received antico-
agulants immediately, but others have reported hemorrhagic
worsening in I to 24% of these patients (18). A lack of
reporting about the details of anticoagulant administration
does not allow analysis of these discrepant results.
Patients with a large infarct appear to be at greater risk
of hemorrhagic worsening after immediate anticoagulation
of embolic stroke. Spontaneous hemorrhagic transformation
may be delayed for several days, but appears most likely
to occur within 48 hours (18, Ill). Thus, as recommended
at a national conference on antithrombotic therapy (18),
immediate anticoagulation of small- to moderate-sized em-
bolic strokes appears advisable if a computed tomographic
scan of the head performed 24 to 48 hours after the stroke
does not indicate hemorrhage and if acute hypertension
(2': 180/100 mm Hg) is not present. The same principles
appear to apply for the continuation of anticoagulant therapy
in patients with a prosthetic heart valve who experience an
embolic stroke during long-term anticoagulant therapy. Be-
cause patients with a large embolic infarct appear to be at
special risk for delayed hemorrhagic transformation, post-
poning anticoagulation for 5 to 7 days is advised before
anticoagulation. This allows time to document that a repeat
computed tomographic scan of the head does not show hem-
orrhagic transformation. Large boluses of heparin and an-
ticoagulant agents beyond 2.0 times the upper limit of nor-
mal should be avoided (suggested therapeutic range 1.5 to
2.0 times the upper limit of the normal activated partial
thromboplastin time).
4) Antithrombotic therapy during pregnancy. Patient
education is critical for women of childbearing age who
have a prosthetic cardiac valve. Pregnancy should ideally
be well planned, and warfarin therapy should be stopped
before conception to avoid the teratogenic effects of warfarin
that are especially prominent during the first trimester. Fetal
wastage is approximately 60% in women who receive war-
farin therapy at the time of conception and during the first
trimester, and it can exceed 80% in women with multiple
prosthetic cardiac valves (112). Warfarin exposure in the
first trimester and possibly exposure therafter may predis-
pose to congenital anomalies, especially nasal hypoplasia,
stippling of bones (chondrodysplasia punctata or Conradi's
syndrome), mental retardation, optic atrophy, microcephaly
and spasticity or hypotonia (112-116). The coumarin de-
rivatives cross the placental barrier, anticoagulate the fetus
and can lead to hemorrhagic complications in the fetus,
especially at the time of delivery.
Thus, anticoagulant therapy should be switched from
warfarin to subcutaneous heparin starting just before con-
ception (or immediatly at the time of suspected conception
such as with flattening of the temperature curve at the time
of anticipated ovulation; radioimmunoassay of the beta-
human chorionic gonadotropin can now detect pregnancy
approximately 5 days before the missed menstrual period).
Administration of subcutaneous heparin should be continued
during the entire pregnancy. Therapy should be started with
10,000 units every 12 hours and adjusted as necessary to
maintain the activated partial thromboplastin times within
1.5 to 2.0 times control when drawn 6 to 11 hours after the
previous dose. A tuberculin syringe with a 25 gauge needle
and heparin at a concentration of 20,000 or 40,000 units/ml
are convenient for repeated injection in the abdominal
region with continued rotation of sites over the entire ab-
dominal wall. A dose of 5,000 units of heparin every 12
hours is insufficient for the prevention of thromboembolism
(116,117). Administration of subcutaneous heparin should
be continued until 1 week before delivery when the patient
should be hospitalized and switched to a heparin infusion,
which is continued until the induction of labor. At that time,
the patient is switched to low dose, subcutaneous heparin,
5,000 units every 8 hours. Fortunately, heparin does not
cross the placental barrier. Warfarin therapy should be re-
started immmediately after delivery. Warfarin can be used
by nursing mothers because only an inactive metabolite of
warfarin is found in breast milk, and it does not change the
prothrombin time of the infant (118,119). To be certain that
there is not an unusual situation, the prothrombin time of
the infant should be checked on one occasion after the nurs-
ing mother is back on warfarin therapy and has been nursing
the infant regularly.
Use of subcutaneous heparin throughout pregnancy ac-
cording to the recommendations outlined has been success-
ful in preventing thromboembolism in 20 patients with a
prosthetic heart valve (Zajarias A, personal communication,
1986). A bioprosthetic heart valve is preferred for women
of childbearing age who wish to bear children because many
do not require long-term anticoagulant therapy. However,
the risk of bioprosthetic calcification in very young women
has to be kept in mind. Platelet inhibitor drugs should be
avoided during pregnancy because aspirin may cause pre-
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mature closure of the ductus arteriosus, and dipyridamole
and sulfinpyrazone have indeterminate effects on the fetus
and are not approved for use during pregnancy.
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